Market Cap (In USD)
21.96 Million
Revenue (In USD)
-
Net Income (In USD)
-34.35 Million
Avg. Volume
42.13 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.05-8.38
- PE
- -1.34
- EPS
- -1.22
- Beta Value
- 0.0
- ISIN
- US38942Q2021
- CUSIP
- 38942Q202
- CIK
- 1534133
- Shares
- 13481900.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. A. Rachel Leheny Ph.D.
- Employee Count
- -
- Website
- https://www.calcimedica.com
- Ipo Date
- 2023-06-14
- Details
- CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
More Stocks
-
LTOUFLarsen & Toubro Limited
LTOUF
-
FHELFFirst Helium Inc.
FHELF
-
601975Nanjing Tanker Corporation
601975
-
AHT-PG
-
PMCUFPro Medicus Limited
PMCUF
-
6816MetaEdge Corporation
6816
-
2517
-
VSEEW